GLP-1 and diabetic nephropathy share key molecular targets

Read full text
Authors: Wanderson Gabriel Gomes de Melo, Regina Lúcia dos Santos Silva, Ianahanna Duarte Santos Soares, Bruno de Sousa Barbosa, Felipe Cardoso de Brito, Napoleão Martins Martins Argôlo Neto, Dayseanny de Oliveira Bezerra
Cited by: 1
References: 40

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists provide renoprotective benefits in diabetes, yet the molecular mechanisms linking GLP-1 signaling to diabetic nephropathy remain poorly defined. This study aimed to identify shared molecular targets between GLP-1 activity and diabetic kidney disease by integrating protein targets of GLP-1 from UniProt with disease-associated genes from GeneCards. The overlapping gene set was analyzed using STRING and Cytoscape ® with MCODE clustering, followed by GO and KEGG enrichment through the clusterProfiler package. Molecular docking with HADDOCK was employed to validate structural interactions between GLP-1 and central network proteins. We identified 17 shared genes, including STAT3, EP300, MAPK1, and INSR, which formed a densely connected cluster enriched in pathways related to insulin response, hypoxia adaptation, apoptosis, and glucose metabolism. Docking analysis demonstrated direct and favorable binding of GLP-1 to STAT3, PIK3R1, and EP300, suggesting noncanonical intracellular mechanisms involving transcriptional regulation and epigenetic modulation. These findings reveal a novel convergence between GLP-1 signaling and diabetic nephropathy pathways, providing mechanistic insights that guide the experimental determination of the underlying molecular interactions. This framework may ultimately contribute to the refinement of renal therapies based on GLP-1 modulation.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes GDF15 and Related Biomarkers

Publication details

Journal / source
Canadian Journal of Physiology and Pharmacology
Publisher
Canadian Science Publishing
Volume
104
Pages
1–10
Publication date
1 January 2026
Language
EN